Anti-FXI/FXIa antibody and use thereof
US12258419B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Apr 6, 2020 |
| Grant date | Mar 25, 2025 |
| Priority date | — |
| Expiry date | May 24, 2042 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/226
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the field of therapeutic monoclonal antibodies, and specifically provides an anti-FXI/FXIa antibody or an antigen-binding fragment thereof, nucleic acid molecules encoding same, and methods for preparing same. The anti-FXI/FXIa antibody or antigen-binding fragment thereof described in the present invention has specificity and high affinity to FXI/FXIa, and can effectively inhibit the activity of FXI/FXIa. Therefore, the present invention further provides a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, and a use thereof in the preparation of a drug which is used for the prevention and/or treatment of diseases or disorders related to coagulation or thromboembolism.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.